Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jul 29, 2021 3:02pm
90 Views
Post# 33626731

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Downgraded to 3, from 8…. With everything going on?!?

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Downgraded to 3, from 8…. With everything going on?!?This is my last post on this subject with you. Note we all are speculating including Ed Nash. I don't know what is the industry standard for partnership in NASH because in my opinion there isn't any, deals get done in many shapes. Now presuming his 85% is correct and THTX ends up with 15% of a multi billion market, add to that they won't need to allocate resources to a costly/lengthy process if it goes all the way. So point is by partnering with another company they take the risks out of the equation and if successful they end of with decent returns. For the potential partner again 85% of a multi billion dollar market by investing about 100M or a bit more in a phase 3 trial is also a good bet. Note the initial investment is only for futility analysis which is far less. Point is the huge size of the market has to be considered too.

<< Previous
Bullboard Posts
Next >>